AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
Log in

NASDAQ:VCYTVeracyte Stock Price, Forecast & News

$26.55
-0.32 (-1.19 %)
(As of 05/27/2020 09:58 AM ET)
Add
Compare
Today's Range
$26.55
Now: $26.55
$27.21
50-Day Range
$19.49
MA: $24.66
$28.11
52-Week Range
$13.90
Now: $26.55
$31.18
Volume973 shs
Average Volume456,475 shs
Market Capitalization$1.33 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.88
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson, LLC and Johnson & Johnson's Lung Cancer Initiative to advance diagnostics of a nasal swab test for early lung cancer detection; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and an agreement with Johnson & Johnson Services, Inc. for the development and commercialization of novel diagnostic tests to detect lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More
Veracyte logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VCYT
CUSIPN/A
Phone650-243-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120.37 million
Book Value$4.60 per share

Profitability

Net Income$-12,600,000.00

Miscellaneous

Employees270
Market Cap$1.33 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive VCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

Veracyte (NASDAQ:VCYT) Frequently Asked Questions

How has Veracyte's stock been impacted by COVID-19 (Coronavirus)?

Veracyte's stock was trading at $23.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VCYT stock has increased by 12.7% and is now trading at $26.55. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Veracyte?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veracyte.

When is Veracyte's next earnings date?

Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Veracyte.

How were Veracyte's earnings last quarter?

Veracyte Inc (NASDAQ:VCYT) announced its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.06. The biotechnology company earned $31.12 million during the quarter, compared to analyst estimates of $30.31 million. Veracyte had a negative net margin of 18.36% and a negative return on equity of 9.68%. View Veracyte's earnings history.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte updated its first quarter 2020 After-Hours earnings guidance on Thursday, April, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $30.5-31.5 million, compared to the consensus revenue estimate of $30.35 million.

What price target have analysts set for VCYT?

3 Wall Street analysts have issued 1-year price objectives for Veracyte's shares. Their forecasts range from $30.00 to $35.00. On average, they expect Veracyte's share price to reach $32.33 in the next year. This suggests a possible upside of 21.8% from the stock's current price. View analysts' price targets for Veracyte.

Has Veracyte been receiving favorable news coverage?

Media headlines about VCYT stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Veracyte earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutVeracyte.

Are investors shorting Veracyte?

Veracyte saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 4,980,000 shares, a decrease of 7.4% from the March 31st total of 5,380,000 shares. Based on an average daily volume of 498,300 shares, the days-to-cover ratio is presently 10.0 days. Currently, 10.5% of the shares of the stock are short sold. View Veracyte's Current Options Chain.

Who are some of Veracyte's key competitors?

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Crispr Therapeutics (CRSP), AbbVie (ABBV), Advanced Micro Devices (AMD), Endologix (ELGX), BlackRock (BLK), InVitae (NVTA), Gilead Sciences (GILD) and Alibaba Group (BABA).

Who are Veracyte's key executives?

Veracyte's management team includes the following people:
  • Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)
  • Mr. Christopher M. Hall, Pres & COO (Age 50)
  • Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)
  • Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 60)
  • Mr. Ashish Kheterpal, Chief Information Officer

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (8.91%), BlackRock Inc. (8.43%), Sumitomo Mitsui Trust Holdings Inc. (6.61%), Nikko Asset Management Americas Inc. (6.57%), Nikko Asset Management Americas Inc. (6.57%) and Invesco Ltd. (6.44%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View institutional ownership trends for Veracyte.

Which major investors are selling Veracyte stock?

VCYT stock was sold by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Lord Abbett & CO. LLC, Nuveen Asset Management LLC, Invesco Ltd., Two Sigma Advisers LP, Acadian Asset Management LLC, Squarepoint Ops LLC, and Atom Investors LP. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, and Keith Kennedy. View insider buying and selling activity for Veracyte.

Which major investors are buying Veracyte stock?

VCYT stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, William Blair Investment Management LLC, Loomis Sayles & Co. L P, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., GW&K Investment Management LLC, and New York State Common Retirement Fund. View insider buying and selling activity for Veracyte.

How do I buy shares of Veracyte?

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $26.55.

How big of a company is Veracyte?

Veracyte has a market capitalization of $1.33 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 270 workers across the globe.

What is Veracyte's official website?

The official website for Veracyte is www.veracyte.com.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.